Related references
Note: Only part of the references are listed.SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis
Larry A. Weinrauch et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2021)
Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
Rozalina G. McCoy et al.
JAMA NETWORK OPEN (2021)
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown et al.
LANCET (2021)
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETES CARE (2020)
Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018
Chintan V. Dave et al.
DIABETES CARE (2020)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
John J. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Influencers of generic drug utilization: A systematic review
Jennifer N. Howard et al.
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Multimorbidity in chronic disease: impact on health care resources and costs
Steven M. McPhail
RISK MANAGEMENT AND HEALTHCARE POLICY (2016)
Sulfonylureas and their use in clinical practice
Daniele Sola et al.
ARCHIVES OF MEDICAL SCIENCE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The impact of medicare part D on prescription drug use by the elderly
Frank R. Lichtenberg et al.
HEALTH AFFAIRS (2007)
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
HD Quan et al.
MEDICAL CARE (2005)
Share Paper
